Stem Cell & Cell-Based Orthobiologic Therapy

Stem cell therapy is a broad term that can refer to several different types of cell-based treatments. Depending on the specific therapy, cells may be obtained from sources such as bone marrow, adipose tissue, umbilical cord-derived tissue, or other biological sources.

These products are not interchangeable. They can differ substantially in cell composition, processing, concentration, viability, and regulatory status. Simply calling a treatment stem cell therapy does not tell you what is actually being injected or what evidence supports its use.

At NuvMed, treatment recommendations are based on the specific diagnosis, available evidence, patient factors, and the characteristics of the biologic product being considered.

Cell-based biologics are being studied because they may interact with the local tissue environment and influence processes such as inflammation, cellular signaling, tissue remodeling, immune responses, blood-vessel formation, and local healing.

However, it is important to distinguish biological potential from proven clinical benefit. Laboratory findings do not necessarily mean an injected cell product will regenerate cartilage, reverse arthritis, or repair a damaged tendon in a human patient. The field continues to evolve, and high-quality clinical research is still needed.

Osteoarthritis is one of the most extensively studied areas of cell-based orthobiologic research. Researchers have investigated whether various preparations can reduce pain, improve function, modify inflammation, or influence cartilage-related processes.

Some clinical studies have reported improvements in pain and function in selected patients. However, studies differ substantially in the type of cells used, preparation methods, dose, injection technique, patient population, and outcome measures. As a result, there is currently no universally accepted stem-cell treatment protocol for osteoarthritis.

Professional orthopedic organizations continue to emphasize the need for stronger evidence and standardized research before these treatments can be considered established therapy for many musculoskeletal conditions.

PRP and cell-based therapies are both orthobiologic treatments, but they are not the same. PRP uses components of your own blood and primarily provides concentrated platelets and plasma proteins. Cell-based therapies involve biological products containing cells or cell-derived components.

The two have different biological characteristics and different levels of clinical evidence depending on the condition. For some musculoskeletal problems, PRP currently has more established evidence than cell-based therapies. In other areas, cell-based approaches remain primarily investigational.

This is an important question every patient should ask.

According to the FDA, the stem-cell products currently approved for use in the United States are certain blood-forming stem-cell products derived from umbilical cord blood, approved for specific disorders affecting the blood-forming system — not for orthopedic conditions.

The FDA states that stem-cell products have not been approved for the treatment of orthopedic conditions such as osteoarthritis, tendonitis, disc disease, back pain, hip pain, knee pain, neck pain, or shoulder pain.

This does not mean cell-based research should be dismissed. It means patients should understand the distinction between established FDA-approved therapies, investigational treatments, and products marketed outside an approved indication or regulatory pathway.

Cell-based treatments are medical procedures and are not risk-free. Potential risks may include:

• ✦Pain or swelling at the injection site
• ✦Bleeding or bruising
• ✦Infection
• ✦Inflammatory reaction
• ✦Injury to surrounding tissues
• ✦Complications related to the collection procedure
• ✦Failure to achieve the expected benefit

The FDA has reported serious adverse events associated with certain unapproved regenerative medicine products, including infections, inflammatory reactions, and neurologic complications. Risks depend heavily on the specific product, how it is processed and administered, and the clinical setting.

Not all stem cell treatments are the same. Before undergoing treatment, patients should understand:

• ✦What type of cells or biologic product is being used
• ✦Where the product comes from
• ✦Whether it is autologous or donor-derived
• ✦How it is processed, and whether cells are cultured or expanded
• ✦How the product is administered
• ✦What clinical evidence supports its use
• ✦What regulatory pathway applies to the product
• ✦What risks are associated with the treatment

A reputable medical practice should be willing to answer these questions clearly.

The exact procedure depends on the therapy being considered. If an autologous product is used, a sample may be obtained from your own body — for example, from bone marrow or another approved source — and processed according to the specific protocol.

The resulting product is administered to the targeted area, which may include a joint, tendon, ligament, or other musculoskeletal structure. Ultrasound or other image guidance may be used to improve accuracy.

Some discomfort is possible during and after the procedure, including temporary soreness, bruising, swelling, aching, or increased pain at the treatment site. If bone marrow is used as the source, there may also be temporary soreness at the collection site.

Cell-based treatments are not expected to work like an anesthetic injection. If a patient responds, improvement may develop gradually over several weeks or longer, depending on the condition, its severity, the location, the product, the protocol, individual healing characteristics, and rehabilitation.

There is currently no reliable way to predict how long an individual patient will benefit. Some studies report improvement lasting months or longer, but long-term outcomes remain an area of ongoing research.

We focus on measurable improvement in pain and function rather than promising a specific duration of benefit.

Cell-based therapy may be considered for carefully selected patients who:

• ✦Have a clearly established musculoskeletal diagnosis
• ✦Continue to experience significant symptoms despite appropriate conservative treatment
• ✦Have realistic expectations regarding potential benefits and limitations
• ✦Understand that evidence varies by condition
• ✦Have been appropriately evaluated for alternative treatments
• ✦Understand the regulatory and investigational status of the proposed therapy

Treatment may not be appropriate for patients with active infection, certain blood or immune-system disorders, certain cancers, severe uncontrolled medical conditions, conditions requiring urgent surgery, or advanced joint disease for which joint replacement is more appropriate.

We believe advanced treatments should be used thoughtfully — not simply because they are new. Before recommending an orthobiologic or cell-based treatment, we consider accurate diagnosis, appropriate patient selection, the strength of evidence for that particular condition, established alternatives, and realistic expectations.

At NuvMed, our approach is to match the treatment to the diagnosis rather than the diagnosis to the treatment.